Belvedere Trading
SPRY icon

Belvedere Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Belvedere Trading’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,143
Closed -$23.2K – 994
2023
Q3 		$23.2K Buy
+6,143
New +$40.3K ﹤0.01% 501
2022
Q3 		– Sell
-64,329
Closed -$277K – 393
2022
Q2 		$277K Buy
+64,329
New +$224K 0.01% 153

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Belvedere Trading's SPRY Position: Q4 2023 in Review

Belvedere Trading sold out of ARS Pharmaceuticals (SPRY) in Q4 2023, closing a stake of 6,143 shares — an estimated $23.2K sold.

Belvedere Trading first reported a position in SPRY in Q2 2022 and held it in 2 quarters. The position peaked at $277K in Q2 2022. 100 funds tracked by Wall St. Rank hold SPRY as of Q4 2023.

  • Belvedere Trading reported no remaining ARS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 6,143 ARS Pharmaceuticals shares in Q4 2023, an estimated $23.2K.
  • Belvedere Trading first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Belvedere Trading's ARS Pharmaceuticals position peaked at $277K in Q2 2022.
  • 100 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.